BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1027 related articles for article (PubMed ID: 30724452)

  • 1. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
    Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
    Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
    Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
    Meng X; Jing R; Qian L; Zhou C; Sun J
    Front Immunol; 2020; 11():1046. PubMed ID: 32636832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
    Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
    Cells; 2019 May; 8(5):. PubMed ID: 31108883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.
    Taheri FH; Hassani M; Sharifzadeh Z; Behdani M; Abdoli S; Sayadi M; Bagherzadeh K; Arashkia A; Abolhassani M
    BMC Biotechnol; 2024 Jan; 24(1):1. PubMed ID: 38178096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
    Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
    Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
    Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
    Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 17. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-Generation Human Epidermal Growth Factor Receptor 2 Chimeric Antigen Receptor Expression on Human T Cells Improves with Two-Signal Activation.
    Dalal AR; Homsy S; Balkhi MY
    Hum Gene Ther; 2018 Aug; 29(8):845-852. PubMed ID: 29373929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.